Green Alpha Advisors LLC Purchases Shares of 33,758 Moderna, Inc. $MRNA

Posted by Stanley Muller on Aug 22nd, 2026

Green Alpha Advisors LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 33,758 shares of the company’s stock, valued at approximately $2,364,000. Moderna comprises approximately 1.6% of Green Alpha Advisors LLC’s investment portfolio, making the stock its 18th largest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Assetmark Inc. increased its position in shares of Moderna by 35.1% during the 1st quarter. Assetmark Inc. now owns 801 shares of the company’s stock valued at $41,000 after purchasing an additional 208 shares during the last quarter. New Mexico Educational Retirement Board lifted its position in Moderna by 1.9% in the 4th quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock worth $463,000 after buying an additional 300 shares during the last quarter. IFP Advisors Inc boosted its stake in Moderna by 5.4% in the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock worth $200,000 after buying an additional 348 shares in the last quarter. Empowered Funds LLC boosted its stake in Moderna by 2.6% in the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock worth $405,000 after buying an additional 353 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators grew its position in Moderna by 16.9% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock valued at $78,000 after acquiring an additional 382 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Moderna news, President Stephen Hoge sold 53,336 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. This represents a 3.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 10.80% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $145.07 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $176.66. The stock has a 50 day moving average price of $68.49 and a two-hundred day moving average price of $56.10. The company has a market capitalization of $57.92 billion, a P/E ratio of -18.16 and a beta of 0.91.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the business earned ($2.13) earnings per share. The business’s revenue was up 2.1% on a year-over-year basis. Analysts expect that Moderna, Inc. will post -6.18 earnings per share for the current year.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Investors are assigning substantial commercial potential to the cancer program. Jefferies reportedly estimates as much as $54 billion in peak global sales and raised its price target to $170, while coverage highlighted the possibility that the trial could establish an oncology opportunity comparable to Merck’s Keytruda franchise. Jefferies sees $54 billion peak sales for Moderna cancer therapy
Positive Sentiment: The favorable Phase 3 outcome has triggered analyst upgrades, including William Blair moving Moderna to Outperform and Bank of America raising its rating to Neutral. The stock also reached a new 12-month high amid renewed enthusiasm for mRNA-based cancer treatments. Moderna raised to Outperform at William Blair
Neutral Sentiment: Trading has been exceptionally volatile for a third consecutive session. Analysts attribute the sharp swings partly to heavy short interest and a subsequent short squeeze, while options activity suggests elevated volatility may persist even without new clinical information. Moderna rallies as mRNA trading whipsaws
Negative Sentiment: Valuation concerns remain significant after the recent surge. JPMorgan raised its price target to $77 but retained an Underweight rating, implying substantial downside from current levels. Commentary also cautioned that the clinical success does not eliminate development, regulatory, manufacturing, commercialization, and pipeline risks for Moderna or other mRNA companies. JPMorgan raises Moderna price target but keeps Underweight rating

Wall Street Analysts Forecast Growth

Several research analysts have commented on MRNA shares. Loop Capital set a $135.00 price target on shares of Moderna in a research note on Wednesday. Bank of America raised shares of Moderna from an “underperform” rating to a “neutral” rating in a report on Wednesday. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research report on Wednesday. Finally, The Goldman Sachs Group boosted their price target on shares of Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $69.50.

Read Our Latest Research Report on Moderna

About Moderna

(Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.